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In order for a tumor mass to get beyond a
critical size, it must develop an associated
vasculature. Over 30 years ago, Folkman
proposed that targeting a tumor vascula-
ture would limit tumor expansion and
could be a useful cancer therapy
(Folkman, 1971); however, the precise
targets and means of inhibiting angiogen-
esis were poorly defined at that time.
More recently, a variety of proangiogenic
and antiangiogenic factors have been
identified and have led to the concept of
the “angiogenic switch,” a process in
which disruption of the normal ratio of
angiogenic stimuli and inhibitors in a
tumor mass allows for autonomous vas-
cularization (Hanahan and Folkman,
1996). The angiogenic switch appears to
be governed by the same genetic alter-
ations that drive malignant conversion:
the activation of oncogenes and the loss
of tumor suppressor genes (Bouck,
1990). Thrombospondin-1 (TSP-1), an
extracellular matrix glycoprotein, was the
first naturally occurring inhibitor of angio-
genesis to be identified (Good et al.,
1990).TSP-1 is a potent inhibitor of in vivo
neovascularization and tumorigenesis
and has been best studied in a variety of
mouse model systems. Overexpression of
TSP-1 in tumor xenografts has been
shown to inhibit tumor cell growth in a
variety of tissue types, while mice with a
genetic susceptibility to breast cancer
show decreased tumor formation in the
presence of a breast-specific TSP-1
transgene (Rodriguez-Manzaneque et al.,
2001). In addition, mice null for both p53
and TSP-1 demonstrate an increased
incidence of osteosarcoma versus mice
lacking p53 alone (Lawler et al., 2001).
Furthermore, tumor xenografts show
increased vascular density and more
rapid growth in mice null for TSP-1, sug-
gesting that TSP-1 expression derived
from either the tumor itself or the tumor
matrix can influence angiogenesis and
tumor growth (Lawler et al., 2001). More
recently, the Id1 null mouse, which fails to
support the growth of tumor xenografts,
has been shown to express increased lev-
els of TSP-1, and Id1 has been shown to
function as a repressor of TSP-1 expres-
sion (Volpert et al., 2002). Data in human
systems has been somewhat equivocal
due to the multiple and varied genetic
alterations occurring in human malignan-
cies and the difficulties in assessing
expression of an extracellular matrix pro-
tein in vivo.
The transcriptional regulation of
thrombospondin-1 reflects the genetic
regulation of tumor cell growth itself.
Several oncogenes have been demon-
strated to repress TSP-1, including onco-
genic ras, c-myc, v-src, c-jun, and Id1
(Volpert et al., 2002), while the tumor
suppressors p53 and PTEN have been
shown to activate TSP-1 expression
(reviewed in Lawler, 2002). While these
studies have provided isolated glimpses
into the ways in which TSP-1 can be reg-
ulated during tumor formation and the
angiogenic switch, no studies have been
able to put together the individual pieces
of the puzzle to identify the critical path-
ways that regulate TSP-1 expression
during the angiogenic switch until now.
In a series of elegant experiments
from Robert Weinberg’s laboratory,
Watnick and colleagues use a genetically
defined tumor model system to evaluate
the molecular regulators of the angio-
genic switch (reviewed in Hahn and
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The formation of a blood supply is critical for tumor growth and metastasis; however, understanding the relationship of
cellular transformation to tumor angiogenesis has been limited by the multifactorial nature of both processes. In this
issue of Cancer Cell, Watnick and colleagues use a genetically defined tumor model system to determine the link
between ras, myc, and angiogenesis and identify Thrombospondin-1 as being the critical regulator of angiogenesis in
this system (Watnick et al., 2003).
Figure 1. Effectors and mediators of the
angiogenic switch driven by Ras as a rheostat
The model established by Watnick et al.
(2003) is shown in the center. Normal, nontu-
morigenic renal cells (Tu−) maintain angio-
genic balance in favor of the inhibitory TSP-1.
Low levels of ras expression induce transfor-
mation, but tumorigenicity of such cells is limit-
ed by threshold size of several millimeters
(Tu±). Although the levels of proangiogenic
VEGF are increased, they are insufficient to
overcome antiangiogenic TSP-1 (angiogenic
switch in the off position). Further increases in
Ras expression have no effect on VEGF levels
but instead trigger signaling events that
involve PI-3 kinase, RhoA, and its target ROCK.
The final known event in the cascade is Myc
activation (via phosphorylation), leading to
the repression of TSP-1, and the angiogenic
switch is “turned on,” allowing unlimited
tumor expansion (Tu+). Shown outside the box
are other factors, both genetic and epigenet-
ic, that modulate the levels of secreted VEGF
and TSP-1 and thus the on/off state of the
angiogenic switch. Factors that enhance
angiogenesis are shown in red, and factors
that inhibit angiogenesis are shown in blue.
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Weinberg, 2002). Using transformed
human embryonic kidney cells and
human mammary epithelial cells, these
investigators note that the angiogenic
switch in tumors derived from these cells
is dependent on the level of expression of
oncogenic Ras. The authors go on to
identify TSP-1 as being the mediator of
the angiogenic switch in these tumors and
provide evidence for the specific inhibition
of TSP-1 expression through a ras-medi-
ated pathway. In order to further define the
pathway from ras to TSP-1, the authors
introduce a dominant-negative version of
c-myc into transformed kidney cells with
high ras expression and demonstrate that
ras-dependent repression of TSP-1 in
transformed kidney cells is dependent on
c-myc function. The authors then go on to
show that, in their tumor model system,
myc function as a target of Ras signaling
and repressor of TSP-1 is dependent
upon phosphorylation of the Myc protein
itself rather than the absolute expression
level of Myc. Myc phosphorylation is then
shown to be mediated through ras signal-
ing via phosphatidyl inositol-3 kinase
(PI3K). Unexpectedly, PI-3 kinase influ-
ences Myc activity not via its conventional
target Akt/PKB, but via guanidine-
exchange factor RhoA and its mediator
ROCK (Figure 1).
The experiments by Watnick et al. in
this issue of Cancer Cell show that rela-
tively low levels of H-Ras in combination
with SV40 early region and hTERT
result in the transformed phenotype of
primary human breast and kidney
epithelial cells. While these cells are
able to form tumors in nude mice, they
are limited in size due to an inability to
induce a vascular supply. Interestingly,
these tumor cells expressed high levels
of the potent angiogenic inducer VEGF;
however, despite increased VEGF lev-
els, these same cells formed only micro-
scopic tumors mimicking dormancy that
normally precedes the switch to
autonomous tumor angiogenesis. This
state of tumor dormancy could be over-
come in two distinct ways: by adding
exogenous VEGF to the system or by
expressing higher levels of oncogenic
ras. Remarkably, higher Ras levels had
no significant effect on VEGF expres-
sion, but instead suppressed the pro-
duction of inhibitory Thrombospondin-1.
Although the concept of angiogenic
switch has been widely accepted,
careful attention has rarely been paid to
both variables in the equation, pro- and
antiangiogenic, since most investigators
tend to focus on one particular pathway.
Watnick and colleagues use a genetical-
ly defined tumor model to clearly delin-
eate the nature of the angiogenic switch
and its role in tumor progression. Taken
as a whole, these studies reinforce the
critical role for TSP-1 as a major effector
of the angiogenic switch and place it
squarely within the path of two major
tumor promoters, ras and myc.
What are the potential clinical impli-
cations of this work? While it is clear that
inhibition of angiogenic stimuli should be
a major target for cancer therapeutics,
this work implies that eliminating repres-
sive effects on protective endogenous
inhibitors of angiogenesis may be an
alternative means of targeting the angio-
genic switch. In addition, developing
small molecules that mimic the antian-
giogenic functions of TSP-1 or other
endogenous inhibitors of angiogenesis
may have potential as therapeutic
agents. The utility of these agents as a
whole is difficult to predict. Although all
tumors require a blood supply to get
beyond a particular mass, the precise
molecules that are tipping the balance to
initiate the angiogenic switch are likely to
be varied and complex and dependent
upon tumor cell type. Only once these
therapeutics have been evaluated clini-
cally will we be able to ascertain the rela-
tive contribution of regulators of the
angiogenic switch to the growth of a par-
ticular human malignancy; however,
genetically defined tumor model systems
like the one used in the above studies
provide useful paradigms from which we
can identify therapeutic targets and
develop therapeutic interventions.
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